Sacituzumab govitecan plus cetuximab for head and neck cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have squamous cell carcinoma of the head and neck (a type of cancer starting in the cells lining your mouth, throat, nose, sinuses, or voice box).
- Your cancer must be advanced (stage IV or spread to other parts of the body) and cannot be cured with surgery or radiation.
- You must have already tried and your cancer progressed after treatment with a PD-1/PD-L1 inhibitor (immunotherapy) with or without chemotherapy.
- You must be 18 years or older, have a good performance status (ECOG 0-1), and have adequate blood counts, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
This study tests a drug called sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) for people with mesothelioma that has already been treated with other therapies. The goal is to see if the drug can shrink tumors and help control the disease.
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This trial tests two medications given before surgery for head and neck cancer. The goal is to see if shrinking the tumor beforehand improves outcomes. If you have operable head and neck squamous cell cancer and are generally healthy, you may be eligible.
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
Hear when a new Nasal Cavity Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.